Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345408 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT02345408 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 54 participants.
The verdict
NCT02345408, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.
Interventions
- DRUG CCX872-B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-02 |
| Est. Completion | 2020-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345408
The ClinicalTrials.gov registry entry for NCT02345408 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CCX872-B is the first listed.
NCT02345408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345408 about?
NCT02345408 is a clinical study titled "Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma". This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.
What is the current status of trial NCT02345408?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2015-02. Estimated completion is 2020-05-06.
What interventions are being tested in trial NCT02345408?
The interventions under investigation include: CCX872-B (DRUG).
Who is sponsoring clinical trial NCT02345408?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.